MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Revenue of MacroGenics, Inc. (MGNX)
Revenue in 2023 (TTM): $58.75 M
According to MacroGenics, Inc.'s latest financial reports the company's current revenue (TTM) is $58.75 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MacroGenics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $58.75 M | $40.88 M | $-158,599,000 | $-9,058,000 | $-9,058,000 |
| 2022 | $151.94 M | $144.56 M | $-121,418,000 | $-119,758,000 | $-120,021,000 |
| 2021 | $75.64 M | $72.99 M | $-202,795,000 | $-202,115,000 | $-190,857,000 |
| 2020 | $97.76 M | $-95,437,000 | $-131,060,000 | $-129,739,000 | $-117,782,000 |
| 2019 | $62.02 M | $-133,285,000 | $-166,340,000 | $-151,811,000 | $-151,811,000 |
| 2018 | $60.12 M | $60.12 M | $-162,927,000 | $-171,453,000 | $-171,453,000 |
| 2017 | $155.52 M | $155.52 M | $-22,143,000 | $-19,626,000 | $-19,626,000 |
| 2016 | $86.58 M | $86.58 M | $-60,042,000 | $-58,528,000 | $-58,528,000 |
| 2015 | $100.85 M | $100.85 M | $-17,319,000 | $-20,140,000 | $-20,140,000 |
| 2014 | $47.26 M | $47.26 M | $-38,315,000 | $-38,313,000 | $-38,313,000 |
| 2013 | $56.75 M | $56.75 M | $1.56 M | $-260,835 | $-260,835 |
| 2012 | $59.65 M | $59.65 M | $9.17 M | $8.36 M | $8.36 M |
| 2011 | $47.05 M | $47.05 M | $6.4 M | $6.72 M | $6.72 M |